近距离放疗后放射性复发前列腺癌挽救性立体定向体部放疗的1期试验
NCT03253744是一项1期试验,旨在确定近距离放疗后局部前列腺癌复发患者挽救性立体定向体部放疗的最大耐受剂量。试验测试40 Gy、42.5 Gy和45 Gy分5次照射三个剂量水平,因DL1和DL2生化控制优异但晚期2级泌尿生殖毒性发生率高而修改方案停止剂量递增,最大耐受剂量定为42.5 Gy分5次。1年和2年生化无进展生存率分别为100%和86%,1例患者在治疗后20个月出现生化失败。
要点
- 挽救性SBRT分5次照射的最大耐受剂量为42.5 Gy(DL2)。
- 1年和2年生化无进展生存率分别为100%和86%,1例在20个月时生化失败。
- 未观察到3至5级治疗相关不良事件,最常见的临床显著毒性为晚期2级泌尿生殖毒性。
核心结论
- 近距离放疗后前列腺内放射性复发的挽救性SBRT最大耐受剂量为42.5 Gy分5次,2年生化无进展生存率为86%,研究后20个月出现1例失败。
- 最常见的临床显著毒性为晚期2级泌尿生殖毒性。
研究设计与样本
- NCT03253744是一项1期试验,采用3+3设计,在最大耐受剂量时扩展3例患者。
- 试验最初设计测试3个治疗剂量水平:40 Gy(DL1)、42.5 Gy(DL2)和45 Gy(DL3),均分5次照射。
- 采用调强技术将处方剂量递送至基于磁共振成像和前列腺特异性膜抗原正电子发射断层成像定义的大体肿瘤体积,同时递送30 Gy至由前列腺腺体定义的选择性体积。
- 毒性采用不良事件通用术语标准第5.0版评分,直至SBRT后2年试验完成。
- 2018年8月至2023年1月期间,9例患者接受挽救性SBRT,中位观察22个月(四分位距20-43个月)。
主要发现
- 未观察到与治疗相关的3至5级不良事件,观察期间未发生剂量限制性毒性。
- 因DL1和DL2生化控制优异且临床显著晚期2级泌尿生殖毒性发生率高,方案修改停止剂量递增,最大耐受剂量被认为是42.5 Gy分5次(DL2)。
- 1年和2年生化无进展生存率分别为100%和86%,代表试验队列中1例患者在治疗后20个月出现生化失败(前列腺特异性抗原[PSA]最低值+2.0)。
- 最常见的临床显著毒性为晚期2级泌尿生殖毒性。
关键数值与推荐
- 剂量限制性毒性定义为SBRT后前3周内发生的任何持续(>4天)3级毒性,或此后发生的任何≥3级泌尿生殖毒性或4级胃肠道毒性;若发生2例剂量限制性毒性则停止递增。
- 最大耐受剂量为42.5 Gy分5次(DL2)。
- 1年生化无进展生存率为100%,2年生化无进展生存率为86%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NCT03253744 is a phase 1 trial with the primary objective to identify the maximum tolerated dose (MTD) of salvage stereotactic body radiation therapy (SBRT) in patients with local prostate cancer recurrence after brachytherapy. Additional objectives included biochemical control and imaging response. METHODS AND MATERIALS: This trial was initially designed to test 3 therapeutic dose levels (DLs): 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) in 5 fractions. Intensity modulation was used to deliver the prescription dose to the magnetic resonance imaging and prostate-specific membrane antigen-based positron emission tomography imaging-defined gross tumor volume while simultaneously delivering 30 Gy to an elective volume defined by the prostate gland. This phase 1 trial followed a 3+3 design with a 3-patient expansion at the MTD. Toxicities were scored until trial completion at 2 years post-SBRT using Common Terminology Criteria for Adverse Events version 5.0. Escalation was halted if 2 dose limiting toxicities occurred, defined as any persistent (>4 days) grade 3 toxicity occurring within the first 3 weeks after SBRT or any grade ≥3 genitourinary (GU) or grade 4 gastrointestinal toxicity thereafter. RESULTS: Between August 2018 and January 2023, 9 patients underwent salvage SBRT and were observed for a median of 22 months (Q1-Q3, 20-43 months). No grade 3 to 5 adverse events related to study treatment were observed; thus, no dose limiting toxicities occurred during the observation period. Escalation was halted by amendment given excellent biochemical control in DL1 and DL2 in the setting of a high incidence of clinically significant late grade 2 GU toxicity. Therefore, the MTD was considered 42.5 Gy in 5 fractions (DL2). One- and 2-year biochemical progression-free survival were 100% and 86%, representing a single patient in the trial cohort with biochemical failure (prostate-specific antigen [PSA] nadir + 2.0) at 20 months posttreatment. CONCLUSIONS: The MTD of salvage SBRT for the treatment of intraprostatic radiorecurrence after brachytherapy was 42.5 Gy in 5 fractions producing an 86% 2-year biochemical progression-free survival rate, with 1 poststudy failure at 20 months. The most frequent clinically significant toxicity was late grade 2 GU toxicity.
引用
- Patel KR, Rydzewski NR, Schott E, et al. A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38428681. doi:10.1016/j.ijrobp.2024.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。